Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy
Portfolio Pulse from Vandana Singh
Concerns are rising over Bluebird Bio's gene therapy as new data shows an increase in cancer cases among treated children. Seven out of 67 children developed blood cancers, up from three cases in June 2022. The FDA had previously approved the therapy, Skysona, despite these concerns. Bluebird Bio has also faced workforce reductions and financial challenges.
October 11, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Bluebird Bio's gene therapy faces increased scrutiny as cancer cases rise among treated children. The FDA had approved Skysona despite earlier cancer concerns. The company is also undergoing workforce reductions to manage financial challenges.
The increase in cancer cases among children treated with Bluebird Bio's gene therapy raises significant safety concerns, likely impacting investor confidence negatively. The FDA's previous approval despite known risks adds to the scrutiny. Additionally, workforce reductions indicate financial strain, which could further affect stock performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100